Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 North America Live Biotherapeutic Products And Microbiome CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 North America C.difficile Market by Country
3.2 North America Crohns Disease Market by Country
3.3 North America IBS Market by Country
3.4 North America Diabetes Market by Country
3.5 North America Others Market by Country
Chapter 4. North America Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1 US Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 US Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 Canada Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 Mexico Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
Unique Offerings 